Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy of Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

  • STATUS
    Enrolling By Invitation
  • participants needed
    6
Send
Updated on 19 February 2024

Summary

The research study is being conducted to study the PD-1 antibody, AGEN2034 alone, or in combination with the CTLA-4 antibody, AGEN1884, in women with recurrent cervical cancer. Subjects will be asked to complete the following research procedures: 12 lead electrocardiogram (ECG) and evaluation of heart function (to determine heart health). Routine blood tests for health and safety reasons (about 1 tablespoon) to measure how many white blood cells, red blood cells, and platelets you have, the function of your liver, kidneys, thyroid and to measure the ability of your blood to clot. Urinalysis. Serum pregnancy test (if you are a woman of childbearing potential). Tumor Imaging Computed Tomography (CT) scan (not required if performed within 21 days prior to the first dose of trial treatment). Collection of stored tumor specimen from previous biopsy to test for PD-L1 expression later. If stored tumor specimen is not available, a fresh biopsy will be required.

Description


FAQ


Details
Condition cervical cancer
Age 99years or below
Clinical Study Identifier03894215
Last Modified on19 February 2024

Eligibility

If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.